Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The ability of transient immunosuppression with a combination of a non-depleting anti-CD4 (NDCD4) antibody and cyclosporine (CyA) to abrogate immune reactivity to both adeno-associated viral vector (AAV) and its transgene product was evaluated. This combination of immunosuppressants resulted in a 20-fold reduction in the resulting anti-AAV8 antibody titres, to levels in naïve mice, following intravenous administration of 2 × 10(12) AAV8 vector particles per kg to immunocompetent mice. This allowed efficient transduction upon secondary challenge with vector pseudotyped with the same capsid. Persistent tolerance did not result, however, as an anti-AAV8 antibody response was elicited upon rechallenge with AAV8 without immunosuppression. The route of vector administration, vector dose, AAV serotype or the concomitant administration of adenoviral vector appeared to have little impact on the ability of the NDCD4 antibody and CyA combination to moderate the primary humoral response to AAV capsid proteins. The combination of NDCD4 and CyA also abrogated the humoral response to the transgene product, that otherwise invariably would occur, following intramuscular injection of AAV5, leading to stable transgene expression. These observations could significantly improve the prospects of using rAAV vectors for chronic disorders by allowing for repeated vector administration and avoiding the development of antibodies to the transgene product.

Original publication

DOI

10.1038/gt.2011.64

Type

Journal article

Journal

Gene Ther

Publication Date

01/2012

Volume

19

Pages

78 - 85

Keywords

Adenoviridae, Animals, Antibodies, Viral, CD4-Positive T-Lymphocytes, Capsid Proteins, Cyclosporine, Dependovirus, Gene Transfer Techniques, Genetic Therapy, Genetic Vectors, Humans, Immunity, Humoral, Immunosuppression, Injections, Intramuscular, Injections, Intravenous, Interferon-beta, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Recombinant Proteins, Transgenes